X4 Pharmaceuticals, Inc. Common Stock (XFOR)

Price$4.11

Value ScoreC

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)0.56%

Price vs S&P 500 (4W)-2.11%

VGM Score49.01

Market Capitalization$381.24M

All Metrics

Book Value / Share (Quarterly)$1.79

P/TBV (Annual)2.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.19%

Cash Flow / Share (Quarterly)$-0.98

Price vs S&P 500 (YTD)-3.18%

Gross Margin (TTM)81.82%

Net Profit Margin (TTM)-1106.30%

EPS (TTM)$-4.64

10-Day Avg Trading Volume0.36M

EPS Excl Extra (TTM)$-4.64

Revenue Growth (5Y)58.59%

EPS (Annual)$-1.87

ROI (Annual)-30.16%

Gross Margin (Annual)83.60%

Net Profit Margin (5Y Avg)-5238.80%

Cash / Share (Quarterly)$2.48

Revenue Growth QoQ (YoY)-90.60%

ROA (Last FY)-27.27%

Revenue Growth TTM (YoY)-71.26%

EBITD / Share (TTM)$-1.64

ROE (5Y Avg)-134.80%

Operating Margin (TTM)-1084.38%

Cash Flow / Share (Annual)$-0.97

P/B Ratio2.26x

P/B Ratio (Quarterly)2.23x

Net Income / Employee (Annual)$-1,760,000

EV / Revenue (TTM)26.72x

Net Interest Coverage (TTM)-17.41x

ROA (TTM)-48.09%

EV / EBITDA (TTM)11.67x

EPS Incl Extra (Annual)$-1.87

Current Ratio (Annual)10.16x

Quick Ratio (Quarterly)9.88x

3-Month Avg Trading Volume0.44M

52-Week Price Return22.44%

Revenue / Employee (TTM)$200,300

Tangible BV / Share (Quarterly)$1.69

P/S Ratio (Annual)10.86x

Asset Turnover (Annual)0.12x

52-Week High$4.83

Operating Margin (5Y Avg)-5090.25%

EPS Excl Extra (Annual)$-1.87

CapEx CAGR (5Y)17.14%

Tangible BV CAGR (5Y)-0.69%

26-Week Price Return16.49%

Quick Ratio (Annual)9.88x

13-Week Price Return32.62%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)10.18x

Enterprise Value$240.86M

Revenue / Share Growth (5Y)-10.81%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-14.43%

Revenue / Employee (Annual)$780,300

Pretax Margin (Annual)-225.44%

Cash / Share (Annual)$2.78

3-Month Return Std Dev81.84%

Net Income / Employee (TTM)$-2,216,000

ROE (Last FY)-42.51%

Net Interest Coverage (Annual)-30.63x

EPS Basic Excl Extra (Annual)$-1.87

Receivables Turnover (TTM)11.11x

Total Debt / Equity (Quarterly)0.45x

EPS Incl Extra (TTM)$-4.64

ROI (TTM)-55.02%

P/S Ratio (TTM)42.29x

Pretax Margin (5Y Avg)-5235.83%

Revenue / Share (Annual)$0.83

Tangible BV / Share (Annual)$1.95

Price vs S&P 500 (52W)-5.76%

Year-to-Date Return7.75%

5-Day Price Return6.68%

EPS Normalized (Annual)$-1.87

ROA (5Y Avg)-51.51%

Net Profit Margin (Annual)-225.55%

Month-to-Date Return5.90%

Cash Flow / Share (TTM)$-0.72

EBITD / Share (Annual)$-2.02

Operating Margin (Annual)-247.44%

LT Debt / Equity (Annual)0.41x

ROI (5Y Avg)-68.33%

LT Debt / Equity (Quarterly)0.45x

EPS Basic Excl Extra (TTM)$-4.64

P/TBV (Quarterly)2.36x

P/B Ratio (Annual)1.96x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-1106.22%

Book Value / Share (Annual)$2.05

Price vs S&P 500 (13W)22.87%

Beta0.37x

Revenue / Share (TTM)$0.10

ROE (TTM)-94.90%

52-Week Low$1.35

vGradeC

gGradeD

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.16est. -0.20

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.20

4.22

4.33

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
XFORX4 Pharmaceuticals, Inc. Common Stock	C	D	B	$4.11
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

X4 Pharmaceuticals develops therapies for rare immune system disorders. Its lead candidate mavorixafor is an oral, once-daily CXCR4 antagonist designed to increase white blood cell mobilization from the bone marrow. The company has two additional CXCR4-based candidates in preclinical development.